Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) traded up 5.2% during trading on Friday . The stock traded as high as $5.32 and last traded at $5.32. 790 shares traded hands during trading, a decline of 95% from the average session volume of 15,878 shares. The stock had previously closed at $5.06.
Innovent Biologics Trading Up 5.2 %
The firm has a fifty day moving average price of $4.60 and a 200 day moving average price of $5.00.
Innovent Biologics Company Profile
Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.
Recommended Stories
- Five stocks we like better than Innovent Biologics
- How to start investing in penny stocks
- How to Build the Ultimate Everything ETF Portfolio
- Energy and Oil Stocks Explained
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Compound Interest and Why It Matters When Investing
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
